Originaltext
Diese Übersetzung bewerten
Mit deinem Feedback können wir Google Übersetzer weiter verbessern
Home
Teladoc Inc
Teladoc Health Reports Second Quarter 2025 Results
Business
Jul 29 2025
26 min read

Teladoc Health Reports Second Quarter 2025 Results

news images

NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended June 30, 2025 (“Second Quarter 2025”). Unless otherwise noted, percentage and other changes are relative to the three months ended June 30, 2024 (“Second Quarter 2024”).

Highlights

  • Second Quarter 2025 revenue of $631.9 million, down 2% year-over-year

  • Second Quarter 2025 net loss of $32.7 million, or $0.19 per share

  • Second Quarter 2025 adjusted EBITDA of $69.3 million, down 23% year-over-year

  • Integrated Care segment revenue of $391.5 million, up 4% year-over-year, and adjusted EBITDA margin of 14.7%

  • BetterHelp segment revenue of $240.4 million, down 9% year-over-year, and adjusted EBITDA margin of 4.9%

  • Paid $550.6 million using cash on hand to retire convertible senior notes due in Second Quarter 2025

  • On July 17, 2025, we entered into a credit agreement providing for a five-year, $300.0 million senior secured revolving credit facility to preserve and enhance our financial and operational flexibility

“I’m pleased with our performance in the second quarter, with consolidated revenue and adjusted EBITDA both at the higher end of our guidance ranges. This reflects continued disciplined execution and builds on our solid results from the first quarter. We continue to work with focus and urgency to advance our strategic priorities, invest in products and capabilities, and deliver solid financial performance,” said Chuck Divita, Chief Executive Officer of Teladoc Health.

“We believe virtual care can be a performance multiplier to help address key challenges in an evolving healthcare landscape. We intend to build on our leadership position by delivering and orchestrating care across patients, providers, platforms, and partners, enhancing the patient experience, improving clinical outcomes, and driving greater value for our clients,” Divita added.

Key Financial Data

 

 

 

 

 

 

 

 

 

 

 

($ in thousands, except per share data, unaudited)

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

Six Months Ended

 

 

 

June 30,

 

 

 

June 30,

 

 

 

 

2025

 

 

 

2024

 

 

Change

 

 

2025

 

 

 

2024

 

 

Change

Revenue

$

631,900

 

 

$

642,444

 

 

(2

)%

 

$

1,261,269

 

 

$

1,288,575

 

 

(2

)%

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

$

(32,660

)

 

$

(837,671

)

 

96

%

 

$

(125,672

)

 

$

(919,560

)

 

86

%

Net loss per share

$

(0.19

)

 

$

(4.92

)

 

96

%

 

$

(0.72

)

 

$

(5.44

)

 

87

%

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA (1)

$

69,311

 

 

$

89,481

 

 

(23

)%

 

$

127,404

 

 

$

152,621

 

 

(17

)%

See note (1) in the Notes section that follows.

Second Quarter 2025

Revenue decreased 2% to $631.9 million from $642.4 million in Second Quarter 2024. Access fees revenue decreased 6% to $523.7 million and other revenue increased 31% to $108.2 million. U.S. revenue decreased 4% to $519.7 million and International revenue increased 10% to $112.2 million.

Integrated Care segment revenue increased 4% to $391.5 million in Second Quarter 2025 and BetterHelp segment revenue decreased 9% to $240.4 million.

Net loss totaled $32.7 million, or $0.19 per share, for Second Quarter 2025, compared to $837.7 million, or $4.92 per share, for Second Quarter 2024. Results for Second Quarter 2025 included stock-based compensation expense of $22.3 million, or $0.13 per share pre-tax, and amortization of intangibles of $88.7 million, or $0.50 per share pre-tax. Net loss for Second Quarter 2025 also included $5.7 million, or $0.03 per share pre-tax, of restructuring costs related to severance costs and costs associated with office space reduction. These items were partially offset by a tax benefit of $9.7 million or $0.06 per share, related to this quarter's acquisition.

Results for Second Quarter 2024 included a non-cash goodwill impairment charge of $790.0 million, or $4.64 per share pre-tax, stock-based compensation expense of $42.1 million, or $0.25 per share pre-tax, amortization of intangibles of $94.9 million, or $0.56 per share pre-tax, and $1.5 million, or $0.01 per share pre-tax, of restructuring costs primarily related to severance payments.

Adjusted EBITDA(1) decreased 23% to $69.3 million, compared to $89.5 million for Second Quarter 2024. Integrated Care segment adjusted EBITDA decreased 10% to $57.5 million in Second Quarter 2025 and BetterHelp segment adjusted EBITDA decreased 53% to $11.9 million in Second Quarter 2025.

Six Months Ended June 30, 2025

Revenue decreased 2% to $1,261.3 million from $1,288.6 million in the first six months of 2024. Access fees revenue decreased 6% to $1,049.4 million and other revenue increased 23% to $211.8 million. U.S. revenue decreased 4% to $1,044.7 million and International revenue increased 8% to $216.6 million.

Integrated Care segment revenue increased 4% to $781.0 million in the first six months of 2025 and BetterHelp segment revenue decreased 10% to $480.3 million.

Net loss totaled $125.7 million, or $0.72 per share, for the first six months of 2025, compared to $919.6 million, or $5.44 per share, for the first six months of 2024. Results for the first six months of 2025 included a non-cash goodwill impairment charge of $59.1 million, or $0.34 per share pre-tax, stock-based compensation expense of $47.5 million, or $0.27 per share pre-tax, and amortization of intangibles of $173.0 million, or $0.99 per share pre-tax. Net loss for the first six months of 2025 also included $10.0 million, or $0.06 per share pre-tax, of restructuring costs related to severance costs and costs associated with office space reduction. These items were partially offset by a discrete tax benefit of $20.1 million, or $0.11 per share, related to the completion of a research and development tax credit study and a tax benefit of $11.1 million, or $0.06 per share, related to the current year's acquisitions.

The non-cash goodwill impairment charge recorded in the first six months of 2025 was the result of the fair value of the Integrated Care segment being less than its carrying value at the time of the acquisition of Catapult Health, LLC.

Results for the first six months of 2024 included a non-cash goodwill impairment charge of $790.0 million, or $4.68 per share pre-tax, stock-based compensation expense of $84.4 million, or $0.50 per share pre-tax, amortization of intangibles of $189.9 million, or $1.12 per share pre-tax, and $11.2 million, or $0.07 per share pre-tax, of restructuring costs primarily related to severance payments.

Adjusted EBITDA(1) decreased 17% to $127.4 million, compared to $152.6 million for the first six months of 2024. Integrated Care segment adjusted EBITDA decreased 3% to $107.8 million in the first six months of 2025 and BetterHelp segment adjusted EBITDA decreased 52% to $19.6 million in the first six months of 2025.

Capex and Cash Flow

Cash flow from operations was $91.4 million in Second Quarter 2025, compared to $88.7 million in Second Quarter 2024, and was $107.4 million in the first six months of 2025, compared to $97.6 million in the first six months of 2024. Capital expenditures and capitalized software development costs (together, “Capex”) were $30.2 million in Second Quarter 2025, compared to $27.7 million in Second Quarter 2024, and were $61.8 million for the first six months of 2025, compared to $63.3 million for the first six months of 2024. Free cash flow was $61.2 million in Second Quarter 2025, compared to $60.9 million in Second Quarter 2024, and was $45.5 million for the first six months of 2025, compared to $34.3 million for the first six months of 2024.

Revolving Credit Facility

On July 17, 2025, we entered into a credit agreement providing for a five-year, $300.0 million senior secured revolving credit facility, subject to customary borrowing conditions. We entered into the revolving credit facility to preserve and enhance our financial and operational flexibility, and we do not currently anticipate borrowing any amounts under the facility. Our capital allocation priorities remain unchanged and include: (i) maintaining a strong balance sheet and an appropriate net leverage profile; (ii) investing in the business to support our strategy through both organic and inorganic initiatives; and (iii) evaluating share repurchases as a potential use of excess cash.

Financial Outlook

The outlook provided below is based on current market conditions and expectations and what we know today.

For the full year of 2025, we expect:

 

 

Full Year 2025 Outlook Range

Revenue

$2,501 - $2,548 million

Adjusted EBITDA

$263 - $294 million

Net loss per share

($1.35) - ($1.00)

Free Cash Flow

$170 - $200 million

U.S. Integrated Care Members (2)

101 - 103 million

 

 

Integrated Care

 

Revenue growth percentage (year-over-year)

1.75% - 3.25%

Adjusted EBITDA margin

14.50% - 15.25%

 

 

BetterHelp

 

Revenue growth percentage (year-over-year)

(9.20%) - (6.80%)

Adjusted EBITDA margin

4.00% - 5.50%


For the third quarter of 2025, we expect:

 

 

3Q 2025 Outlook Range

Revenue

$614 - $636 million

Adjusted EBITDA

$56 - $70 million

Net loss per share

($0.35) - ($0.20)

U.S. Integrated Care Members (2)

101.5 - 102.5 million

 

 

Integrated Care

 

Revenue growth percentage (year-over-year)

(0.50%) - 2.25%

Adjusted EBITDA margin

14.00% - 15.50%

 

 

BetterHelp

 

Revenue growth percentage (year-over-year)

(9.75%) - (5.00%)

Adjusted EBITDA margin

1.00% - 3.75%

See note (2) in the Notes section that follows.

Earnings Conference Call

The Second Quarter 2025 earnings conference call and webcast will be held Tuesday, July 29, 2025 at 4:30 p.m. E.T. The conference call can be accessed by dialing 1-833-470-1428 for U.S. participants and using the access code #606269. For international participants, please visit the following link for global dial-in numbers: https://www.netroadshow.com/conferencing/global-numbers?confId=85796. A live audio webcast will also be available online at http://ir.teladoc.com/news-and-events/events-and-presentations/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Teladoc Health

Teladoc Health (NYSE: TDOC) is the global leader in virtual care. The company is delivering and orchestrating care across patients, care providers, platforms, and partners — transforming virtual care into a catalyst for how better health happens. Through our relationships with health plans, employers, providers, health systems and consumers, we are enabling more access, driving better outcomes, extending provider capacity and lowering costs. Learn more at teladochealth.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, the information under the caption “Financial Outlook” and statements we make regarding future financial or operating results, future numbers of members, BetterHelp paying users or clients, litigation outcomes, regulatory developments, market developments, new products and growth strategies, and the effects of any of the foregoing on our future results of operations or financial condition.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market conditions and receptivity to our services and offerings, including our ability to effectively compete; (iii) results of litigation or regulatory actions; (iv) the loss of one or more key clients or the loss of a significant number of members or BetterHelp paying users; (v) changes in valuations or useful lives of our assets; (vi) changes to our abilities to recruit and retain qualified providers into our network; (vii) the impact of and risk related to impairment losses with respect to goodwill or other assets; (viii) the success of our operational review of the company to achieve a more balanced approach to growth and margin; and (ix) imposed and threatened tariffs by the United States and its trading partners, and any resulting disruptions or inefficiencies in our supply chain. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to, our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as filed with the SEC.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

TELADOC HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share data, unaudited)

 

Three Months Ended
June 30,

 

Six Months Ended
June 30,

 

 

2025

 

 

 

2024

 

 

 

2025

 

 

 

2024

 

Revenue

$

631,900

 

 

$

642,444

 

 

$

1,261,269

 

 

$

1,288,575

 

Costs and expenses:

 

 

 

 

 

 

 

Cost of revenue (exclusive of depreciation and amortization, which are shown separately below)

 

190,537

 

 

 

188,059

 

 

 

387,366

 

 

 

382,597

 

Advertising and marketing

 

167,547

 

 

 

170,270

 

 

 

335,732

 

 

 

353,599

 

Sales

 

49,951

 

 

 

50,438

 

 

 

98,644

 

 

 

104,802

 

Technology and development

 

68,784

 

 

 

76,751

 

 

 

138,742

 

 

 

158,139

 

General and administrative

 

108,114

 

 

 

109,552

 

 

 

220,888

 

 

 

221,249

 

Goodwill impairment

 

 

 

 

790,000

 

 

 

59,138

 

 

 

790,000

 

Acquisition, integration, and transformation costs

 

2,658

 

 

 

457

 

 

 

4,846

 

 

 

830

 

Restructuring costs

 

5,692

 

 

 

1,500

 

 

 

10,039

 

 

 

11,173

 

Amortization of intangible assets

 

88,664

 

 

 

94,862

 

 

 

172,968

 

 

 

189,919

 

Depreciation of property and equipment

 

4,338

 

 

 

1,703

 

 

 

7,902

 

 

 

4,537

 

Total costs and expenses

 

686,285

 

 

 

1,483,592

 

 

 

1,436,265

 

 

 

2,216,845

 

Loss from operations

 

(54,385

)

 

 

(841,148

)

 

 

(174,996

)

 

 

(928,270

)

Interest income

 

(10,064

)

 

 

(13,572

)

 

 

(22,738

)

 

 

(27,514

)

Interest expense

 

4,473

 

 

 

5,648

 

 

 

10,238

 

 

 

11,297

 

Other expense (income), net

 

(8,371

)

 

 

563

 

 

 

(10,806

)

 

 

933

 

Loss before provision for income taxes

 

(40,423

)

 

 

(833,787

)

 

 

(151,690

)

 

 

(912,986

)

Provision for income taxes

 

(7,763

)

 

 

3,884

 

 

 

(26,018

)

 

 

6,574

 

Net loss

$

(32,660

)

 

$

(837,671

)

 

$

(125,672

)

 

$

(919,560

)

 

 

 

 

 

 

 

 

Net loss per share, basic and diluted

$

(0.19

)

 

$

(4.92

)

 

$

(0.72

)

 

$

(5.44

)

 

 

 

 

 

 

 

 

Weighted-average shares used to compute basic and diluted net loss per share

 

175,917,380

 

 

 

170,229,583

 

 

 

175,040,625

 

 

 

168,980,165

 


Stock-based Compensation Summary

Compensation expense for stock-based awards was classified as follows (in thousands, unaudited):

 

Three Months Ended
June 30,

 

Six Months Ended
June 30,

 

 

2025

 

 

2024

 

 

2025

 

 

2024

Cost of revenue (exclusive of depreciation and amortization, which are shown separately)

$

506

 

$

1,313

 

$

1,079

 

$

2,707

Advertising and marketing

 

1,302

 

 

3,378

 

 

2,805

 

 

7,167

Sales

 

3,594

 

 

6,953

 

 

7,853

 

 

14,920

Technology and development

 

4,247

 

 

9,683

 

 

10,032

 

 

18,982

General and administrative

 

12,695

 

 

20,780

 

 

25,738

 

 

40,656

Total stock-based compensation expense (3)

$

22,344

 

$

42,107

 

$

47,507

 

$

84,432

See note (3) in the Notes section that follows.

Revenues

 

Three Months Ended

 

 

 

Six Months Ended

 

 

 

June 30,

 

 

 

June 30,

 

 

($ in thousands, unaudited)

 

2025

 

 

2024

 

Change

 

 

2025

 

 

2024

 

Change

Revenue by Type

 

 

 

 

 

 

 

 

 

 

 

Access Fees

$

523,703

 

$

559,648

 

(6

)%

 

$

1,049,439

 

$

1,116,822

 

(6

)%

Other

 

108,197

 

 

82,796

 

31

%

 

 

211,830

 

 

171,753

 

23

%

Total Revenue

$

631,900

 

$

642,444

 

(2

)%

 

$

1,261,269

 

$

1,288,575

 

(2

)%

 

 

 

 

 

 

 

 

 

 

 

 

Revenue by Geography

 

 

 

 

 

 

 

 

 

 

 

U.S. Revenue

$

519,689

 

$

540,802

 

(4

)%

 

$

1,044,659

 

$

1,088,402

 

(4

)%

International Revenue

 

112,211

 

 

101,642

 

10

%

 

 

216,610

 

 

200,173

 

8

%

Total Revenue

$

631,900

 

$

642,444

 

(2

)%

 

$

1,261,269

 

$

1,288,575

 

(2

)%


Summary Operating Metrics

Consolidated

 

Three Months Ended

 

 

 

 

Six Months Ended

 

 

 

 

June 30,

 

 

 

 

June 30,

 

 

 

(In millions)

2025

 

2024

 

Change

 

 

2025

 

2024

 

Change

 

Total Visits

4.1

 

4.2

 

(3

)%

 

8.6

 

8.8

 

(3

)%


Integrated Care

 

As of June 30,

 

 

(In millions)

2025

 

2024

 

Change

U.S. Integrated Care Members (2)

102.4

 

92.4

 

11

%

Chronic Care Program Enrollment (4)

1.117

 

1.173

 

(5

)%


 

Three Months Ended

 

 

 

 

Six Months Ended

 

 

 

 

June 30,

 

 

 

 

June 30,

 

 

 

 

 

2025

 

 

2024

 

Change

 

 

 

2025

 

 

2024

 

Change

 

Average Monthly Revenue
Per U.S. Integrated Care Member (5)

$

1.27

 

$

1.36

 

(7

)%

 

$

1.27

 

$

1.37

 

(7

)%


BetterHelp

 

Average for

 

 

 

 

Average for

 

 

 

 

Three Months Ended

 

 

 

 

Six Months Ended

 

 

 

 

June 30,

 

 

 

 

June 30,

 

 

 

(In millions)

2025

 

2024

 

Change

 

 

2025

 

2024

 

Change

 

BetterHelp Paying Users (6)

0.388

 

0.407

 

(5

)%

 

0.393

 

0.411

 

(4

)%

See notes (2), (4), (5), and (6) in the Notes section that follows.

Operating Results by Segment (see note (7) in the Notes section that follows)

The following table presents operating results by reportable segment for the periods indicated:

 

Three Months Ended

 

 

 

Six Months Ended

 

 

 

June 30,

 

 

 

June 30,

 

 

($ in thousands, unaudited)

 

2025

 

 

 

2024

 

 

Change

 

 

2025

 

 

 

2024

 

 

Change

Integrated Care

 

 

 

 

 

 

 

 

 

 

 

Revenue

$

391,510

 

 

$

377,421

 

 

4

%

 

$

780,978

 

 

$

754,532

 

 

4

%

Adjusted EBITDA

$

57,450

 

 

$

64,028

 

 

(10

)%

 

$

107,829

 

 

$

111,702

 

 

(3

)%

Adjusted EBITDA Margin %

 

14.7

%

 

 

17.0

%

 

 

 

 

13.8

%

 

 

14.8

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

BetterHelp

 

 

 

 

 

 

 

 

 

 

 

Therapy Services

$

235,403

 

 

$

259,073

 

 

(9

)%

 

$

469,841

 

 

$

522,785

 

 

(10

)%

Other Wellness Services

 

4,987

 

 

 

5,950

 

 

(16

)%

 

 

10,450

 

 

 

11,258

 

 

(7

)%

Total Revenue

$

240,390

 

 

$

265,023

 

 

(9

)%

 

$

480,291

 

 

$

534,043

 

 

(10

)%

Adjusted EBITDA

$

11,861

 

 

$

25,453

 

 

(53

)%

 

$

19,575

 

 

$

40,919

 

 

(52

)%

Adjusted EBITDA Margin %

 

4.9

%

 

 

9.6

%

 

 

 

 

4.1

%

 

 

7.7

%

 

 


TELADOC HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands, unaudited)

 

Six Months Ended
June 30,

 

 

2025

 

 

 

2024

 

Cash flows from operating activities:

 

 

 

Net loss

$

(125,672

)

 

$

(919,560

)

Adjustments to reconcile net loss to net cash flows from operating activities:

 

 

 

Goodwill impairment

 

59,138

 

 

 

790,000

 

Amortization of intangible assets

 

172,968

 

 

 

189,919

 

Depreciation of property and equipment

 

7,902

 

 

 

4,537

 

Amortization of right-of-use assets

 

4,190

 

 

 

4,902

 

Provision for allowances for doubtful accounts

 

377

 

 

 

810

 

Stock-based compensation

 

47,507

 

 

 

84,432

 

Deferred income taxes

 

(34,072

)

 

 

1,368

 

Other, net

 

2,049

 

 

 

2,695

 

Changes in operating assets and liabilities:

 

 

 

Accounts receivable

 

(8,497

)

 

 

(2,971

)

Prepaid expenses and other current assets

 

(16,434

)

 

 

(13,017

)

Inventory

 

861

 

 

 

(6,032

)

Other assets

 

7,616

 

 

 

676

 

Accounts payable

 

19,278

 

 

 

12,614

 

Accrued expenses and other current liabilities

 

(5,149

)

 

 

154

 

Accrued compensation

 

(9,545

)

 

 

(45,802

)

Deferred revenue

 

(6,084

)

 

 

(1,638

)

Operating lease liabilities

 

(5,170

)

 

 

(5,424

)

Other liabilities

 

(3,912

)

 

 

(60

)

Net cash provided by operating activities

 

107,351

 

 

 

97,603

 

Cash flows from investing activities:

 

 

 

Capital expenditures

 

(3,994

)

 

 

(3,061

)

Capitalized software development costs

 

(57,824

)

 

 

(60,199

)

Proceeds from the sale of investment

 

740

 

 

 

 

Acquisition accounted for as a business combination, net of cash acquired

 

(65,302

)

 

 

 

Asset acquisition resulting in net intangible assets

 

(29,569

)

 

 

 

Payments for investments

 

(27,075

)

 

 

 

Other, net

 

60

 

 

 

 

Net cash used in investing activities

 

(182,964

)

 

 

(63,260

)

Cash flows from financing activities:

 

 

 

Proceeds from the exercise of stock options

 

81

 

 

 

2,677

 

Proceeds from employee stock purchase plan

 

1,384

 

 

 

2,798

 

Repayment of convertible senior notes

 

(550,629

)

 

 

 

Other, net

 

 

 

 

81

 

Net cash (used in) provided by financing activities

 

(549,164

)

 

 

5,556

 

Net (decrease) increase in cash and cash equivalents

 

(624,777

)

 

 

39,899

 

Effect of foreign currency exchange rate changes

 

6,071

 

 

 

(1,191

)

Cash and cash equivalents at beginning of the period

 

1,298,327

 

 

 

1,123,675

 

Cash and cash equivalents at end of the period

$

679,621

 

 

$

1,162,383

 


CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data, unaudited)

 

June 30,
2025

 

December 31,
2024

ASSETS

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

679,621

 

 

$

1,298,327

 

Accounts receivable, net of allowance for doubtful accounts of $4,914 and $5,134 at June 30, 2025 and December 31, 2024, respectively

 

225,431

 

 

 

214,146

 

Inventories

 

38,159

 

 

 

38,138

 

Prepaid expenses and other current assets

 

130,059

 

 

 

113,296

 

Total current assets

 

1,073,270

 

 

 

1,663,907

 

Property and equipment, net

 

27,667

 

 

 

29,487

 

Goodwill

 

283,190

 

 

 

283,190

 

Intangible assets, net

 

1,383,306

 

 

 

1,431,360

 

Operating lease—right-of-use assets

 

25,501

 

 

 

27,092

 

Other assets

 

101,070

 

 

 

81,488

 

Total assets

$

2,894,004

 

 

$

3,516,524

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

54,434

 

 

$

33,130

 

Accrued expenses and other current liabilities

 

202,304

 

 

 

202,157

 

Accrued compensation

 

70,332

 

 

 

76,229

 

Deferred revenue—current

 

74,697

 

 

 

79,296

 

Convertible senior notes, net—current

 

 

 

 

550,723

 

Total current liabilities

 

401,767

 

 

 

941,535

 

Other liabilities

 

4,245

 

 

 

720

 

Operating lease liabilities, net of current portion

 

32,047

 

 

 

32,135

 

Deferred revenue, net of current portion

 

10,694

 

 

 

9,786

 

Deferred taxes, net

 

29,947

 

 

 

49,851

 

Convertible senior notes, net—non-current

 

993,165

 

 

 

991,418

 

Total liabilities

 

1,471,865

 

 

 

2,025,445

 

Commitments and contingencies

 

 

 

Stockholders’ equity:

 

 

 

Common stock, $0.001 par value; 300,000,000 shares authorized; 176,608,056 shares and 173,405,016 shares issued and outstanding as of June 30, 2025 and December 31, 2024 respectively

 

177

 

 

 

173

 

Additional paid-in capital

 

17,812,932

 

 

 

17,759,194

 

Accumulated deficit

 

(16,355,572

)

 

 

(16,229,900

)

Accumulated other comprehensive loss

 

(35,398

)

 

 

(38,388

)

Total stockholders’ equity

 

1,422,139

 

 

 

1,491,079

 

Total liabilities and stockholders’ equity

$

2,894,004

 

 

$

3,516,524

 


Non-GAAP Financial Measures:

To supplement our financial information presented in accordance with generally accepted accounting principles in the United States (“GAAP”), we use certain non-GAAP financial measures to clarify and enhance an understanding of past performance, which include adjusted EBITDA and free cash flow. We believe that the presentation of these financial measures enhances an investor’s understanding of our financial performance, and are commonly used by investors to evaluate our performance and that of our competitors. We further believe that these financial measures are useful to assess our operating performance and financial and business trends from period-to-period by excluding certain items that we believe are not representative of our core business, and that free cash flow reflects an additional way of viewing our liquidity that, when viewed together with GAAP results, provides management, investors, and other users of our financial information with a more complete understanding of factors and trends affecting our cash flows. We use these non-GAAP financial measures for business planning purposes and in measuring our performance relative to that of our competitors. We utilize adjusted EBITDA as a key measure of our performance.

Adjusted EBITDA consists of net loss before provision for income taxes; other expense (income), net; interest income; interest expense; depreciation of property and equipment; amortization of intangible assets; restructuring costs; acquisition, integration, and transformation cost; goodwill impairment; and stock-based compensation.

Free cash flow is net cash provided by operating activities less capital expenditures and capitalized software development costs.

Our use of these non-GAAP terms may vary from that of others in our industry, and other companies may calculate such measures differently than we do, limiting their usefulness as comparative measures.

Non-GAAP measures have important limitations as analytical tools and you should not consider them in isolation, and they should not be considered as an alternative to net loss before provision for income taxes, net loss, net loss per share, net cash from operating activities or any other measures derived in accordance with GAAP. Some of these limitations are:

  • adjusted EBITDA eliminates the impact of the provision for income taxes on our results of operations, and does not reflect other expense (income), net, interest income, or interest expense;

  • adjusted EBITDA does not reflect restructuring costs. Restructuring costs may include certain lease impairment costs, certain losses related to early lease terminations, and severance;

  • adjusted EBITDA does not reflect significant acquisition, integration, and transformation costs. Acquisition, integration and transformation costs include investment banking, financing, legal, accounting, consultancy, integration, fair value changes related to contingent consideration, and certain other transaction costs related to mergers and acquisitions. It also includes costs related to certain business transformation initiatives focused on integrating and optimizing various operations and systems, including upgrading our customer relationship management and enterprise resource planning systems. These transformation cost adjustments made to our results do not represent normal, recurring, operating expenses necessary to operate the business but rather, incremental costs incurred in connection with our acquisition and integration activities;

  • adjusted EBITDA does not reflect goodwill impairment charges; and

  • adjusted EBITDA does not reflect the significant non-cash stock-based compensation expense which should be viewed as a component of recurring operating costs.

In addition, although amortization of intangible assets and depreciation of property and equipment are non-cash charges, the assets being amortized and depreciated will often have to be replaced in the future, and adjusted EBITDA does not reflect any expenditures for such replacements.

We compensate for these limitations by using these non-GAAP measures along with other comparative tools, together with GAAP measurements, to assist in the evaluation of operating performance. Such GAAP measurements include net loss, net loss per share, net cash provided by operating activities, and other performance measures.

In evaluating these financial measures, you should be aware that in the future we may incur expenses similar to those eliminated in this presentation. Our presentation of these non-GAAP measures should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.

The following is a reconciliation of net loss, the most directly comparable GAAP financial measure, to adjusted EBITDA:

Reconciliation of GAAP Net Loss to Adjusted EBITDA
(In thousands, unaudited)

 

 

 

 

 

 

 

 

 

Outlook in millions (8)

 

Three Months Ended
June 30,

 

Six Months Ended
June 30,

 

Third Quarter

 

Full Year

 

 

2025

 

 

 

2024

 

 

 

2025

 

 

 

2024

 

 

2025

 

2025

Net income (loss)

$

(32,660

)

 

$

(837,671

)

 

$

(125,672

)

 

$

(919,560

)

 

$(62) - (35)

 

$(238) - (176)

Add:

 

 

 

 

 

 

 

 

 

 

 

Provision for income taxes

 

(7,763

)

 

 

3,884

 

 

 

(26,018

)

 

 

6,574

 

 

 

 

 

Other expense (income), net

 

(8,371

)

 

 

563

 

 

 

(10,806

)

 

 

933

 

 

 

 

 

Interest expense

 

4,473

 

 

 

5,648

 

 

 

10,238

 

 

 

11,297

 

 

 

 

 

Interest income

 

(10,064

)

 

 

(13,572

)

 

 

(22,738

)

 

 

(27,514

)

 

 

 

 

Depreciation of property and equipment

 

4,338

 

 

 

1,703

 

 

 

7,902

 

 

 

4,537

 

 

 

 

 

Amortization of intangible assets

 

88,664

 

 

 

94,862

 

 

 

172,968

 

 

 

189,919

 

 

 

 

 

Restructuring costs

 

5,692

 

 

 

1,500

 

 

 

10,039

 

 

 

11,173

 

 

 

 

 

Acquisition, integration, and transformation costs

 

2,658

 

 

 

457

 

 

 

4,846

 

 

 

830

 

 

 

 

 

Goodwill impairment

 

 

 

 

790,000

 

 

 

59,138

 

 

 

790,000

 

 

 

 

 

Stock-based compensation

 

22,344

 

 

 

42,107

 

 

 

47,507

 

 

 

84,432

 

 

 

 

 

Total Adjustments

 

101,971

 

 

 

927,152

 

 

 

253,076

 

 

 

1,072,181

 

 

91 - 132

 

439 - 532

Consolidated Adjusted EBITDA

$

69,311

 

 

$

89,481

 

 

$

127,404

 

 

$

152,621

 

 

$56 - 70

 

$263 - 294

 

 

 

 

 

 

 

 

 

 

 

 

Segment Adjusted EBITDA

 

 

 

 

 

 

 

 

 

 

 

Integrated Care

$

57,450

 

 

$

64,028

 

 

$

107,829

 

 

$

111,702

 

 

 

 

 

BetterHelp

 

11,861

 

 

 

25,453

 

 

 

19,575

 

 

 

40,919

 

 

 

 

 

Consolidated Adjusted EBITDA

$

69,311

 

 

$

89,481

 

 

$

127,404

 

 

$

152,621

 

 

 

 

 

See note (8) in the Notes section that follows.

The following is a reconciliation of net cash provided by operating activities, the most directly comparable GAAP financial measure, to free cash flow:

Reconciliation of GAAP Net Cash Provided by Operating Activities to Free Cash Flow
(In thousands, unaudited)

 

Three Months Ended

 

Six Months Ended

 

Outlook (9)

 

June 30,

 

June 30,

 

Full Year

 

 

2025

 

 

 

2024

 

 

 

2025

 

 

 

2024

 

 

2025 (in millions)

Net cash provided by operating activities

$

91,432

 

 

$

88,683

 

 

$

107,351

 

 

$

97,603

 

 

$309 - 329

Capital expenditures

 

(1,268

)

 

 

(1,912

)

 

 

(3,994

)

 

 

(3,061

)

 

 

Capitalized software development costs

 

(28,965

)

 

 

(25,836

)

 

 

(57,824

)

 

 

(60,199

)

 

 

Capex

 

(30,233

)

 

 

(27,748

)

 

 

(61,818

)

 

 

(63,260

)

 

(139) - (129)

Free Cash Flow

$

61,199

 

 

$

60,935

 

 

$

45,533

 

 

$

34,343

 

 

$170 - 200

See note (9) in the Notes section that follows.

Notes:

  1. A reconciliation of each non-GAAP measure to the most comparable measure under GAAP has been provided in this press release in the accompanying tables. An explanation of these non-GAAP measures is also included under the heading “Non-GAAP Financial Measures.”

  2. U.S. Integrated Care Members represent the number of unique individuals who have paid access and visit fee only access to our suite of integrated care services in the U.S. at the end of the applicable period.

  3. Excluding the amount capitalized related to software development projects.

  4. Chronic Care Program Enrollment represents the total number of enrollees across our suite of chronic care programs at the end of the applicable period.

  5. Average monthly revenue per U.S. Integrated Care member is calculated by dividing the total revenue generated from the Integrated Care segment by the average number of U.S. Integrated Care Members (see note 2) during the applicable period.

  6. BetterHelp Paying Users represent the average number of global monthly paying users of our BetterHelp therapy services during the applicable period, including both those who pay directly out-of-pocket and those who utilize their insurance coverage.

  7. We have two segments: Integrated Care and BetterHelp. The Integrated Care segment includes a suite of global virtual medical services including general medical, expert medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. The BetterHelp segment includes virtual therapy and other wellness services provided on a global basis which are predominantly marketed and sold on a direct-to-consumer basis.

  8. We have not provided a full line-item reconciliation for net loss to adjusted EBITDA outlook because we do not provide an outlook on the individual reconciling items between net loss and adjusted EBITDA. This is due to the uncertainty as to timing, and the potential variability, of the individual reconciling items such as impairments, stock-based compensation and the related tax impact, provision for income taxes, acquisition, integration, and transformation costs, and restructuring costs, the effect of which may be significant. Accordingly, a full line-item reconciliation of the GAAP measure to the corresponding non-GAAP financial measure outlook is not available without unreasonable effort.

  9. We have not provided a line-item reconciliation for free cash flow to net cash from operating activities for this future period because we believe such a reconciliation would imply a degree of precision and certainty that could be confusing to investors and we are unable to reasonably predict certain items contained in the GAAP measure without unreasonable efforts.

Investors:
Michael Minchak
617-444-9612
ir@teladochealth.com

Media:
Lou Serio
202-569-9715
pr@teladochealth.com